International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - sPositive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, the company has been strongly shaken and is now hoping for calmer waters in order to drive its clinical development forward with greater focus.
ADVERTISEMENT